Physician profile
Charles A Sninsky
NPI 1811912561
$982,924.05
in general payments reported to CMS, 2019-2025
20 companies · $180K in 2025
The $180K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261K · 2020: $72K · 2021: $86K · 2022: $131K · 2023: $109K · 2024: $143K · 2025: $180K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $336K · Travel and Lodging: $54K · Consulting Fee: $32K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $335,501.49 |
| Travel and Lodging | $53,932.00 |
| Consulting Fee | $32,350.00 |
| Food and Beverage | $10,898.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $278,262.59 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $187,145.82 | 2019-2023 | Stelara |
| Abbvie INC. | $185,899.72 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $70,539.36 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $65,418.54 | 2020-2024 | Zeposia |
| Celgene Corporation | $65,329.28 | 2019-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $62,904.49 | 2019-2025 | Entyvio |
| Lilly USA, LLC | $53,589.75 | 2023-2025 | Omvoh |
| Ucb, INC. | $11,400.06 | 2019 | |
| Ferring Pharmaceuticals INC. | $2,092.00 | 2021 | |
| Johnson & Johnson Health Care Systems INC. | $107.49 | 2022 | |
| Nestle Healthcare Nutrition INC. | $102.21 | 2021-2022 | |
| Madrigal Pharmaceuticals | $28.42 | 2025 | Rezdiffra |
| Medtronic, INC. | $24.96 | 2024 | Nexpowder |
| Otsuka America Pharmaceutical, INC. | $24.39 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $20.60 | 2024 | Esophyx |
| Allergan, INC. | $19.55 | 2019 | |
| Cook Medical LLC | $11.35 | 2021 | |
| Phathom Pharmaceuticals, INC. | $3.47 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Sninsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.